Beta Bionics, Inc. (BBNX)

Market Cap	814.46M
Revenue (ttm)	88.57M
Net Income (ttm)	-77.84M
Shares Out	44.02M
EPS (ttm)	-2.50
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,397,386
Open	17.71
Previous Close	17.79
Day's Range	17.39 - 18.61
52-Week Range	8.89 - 32.71
Beta	n/a
Analysts	Strong Buy
Price Target	29.75 (+60.81%)
Earnings Date	Feb 17, 2026

About BBNX

Beta Bionics, Inc., a commercial-stage medical device company, engages in the design, development, and commercialization of solutions to enhance the health and quality of life of insulin-requiring people with diabetes. It offers iLet Bionic Pancreas, an insulin delivery device for the treatment of type 1 diabetes in adults and children six years of age and older. The company is developing Patch Pump, an insulin pump that is designed to adhere directly to the skin and administer insulin without the need for tubing; Bihormonal iLet, which combine...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Jan 30, 2025
• Employees: 294
• Stock Exchange: NASDAQ
• Ticker Symbol: BBNX
• Website: https://www.betabionics.com

Financial Performance

In 2024, Beta Bionics's revenue was $65.12 million, an increase of 442.93% compared to the previous year's $12.00 million. Losses were -$54.76 million, 24.2% more than in 2023.

Analyst Summary

According to 12 analysts, the average rating for BBNX stock is "Strong Buy." The 12-month stock price target is $29.75, which is an increase of 60.81% from the latest price.

Price Target

$29.75

(60.81% upside)

Analyst Consensus: Strong Buy